QQQ   423.19 (-0.62%)
AAPL   166.91 (-0.65%)
MSFT   405.39 (-1.57%)
META   501.50 (+1.48%)
GOOGL   156.22 (+0.48%)
AMZN   179.00 (-1.26%)
TSLA   150.48 (-3.20%)
NVDA   844.72 (+0.52%)
AMD   154.17 (+0.10%)
NIO   4.02 (+2.81%)
BABA   68.88 (+0.09%)
T   16.23 (+0.68%)
F   12.01 (-0.25%)
MU   112.61 (-3.20%)
GE   153.90 (-1.14%)
CGC   8.12 (+25.12%)
DIS   112.83 (-0.10%)
AMC   2.92 (-2.01%)
PFE   25.33 (-0.35%)
PYPL   62.22 (-1.64%)
XOM   118.24 (-0.33%)
QQQ   423.19 (-0.62%)
AAPL   166.91 (-0.65%)
MSFT   405.39 (-1.57%)
META   501.50 (+1.48%)
GOOGL   156.22 (+0.48%)
AMZN   179.00 (-1.26%)
TSLA   150.48 (-3.20%)
NVDA   844.72 (+0.52%)
AMD   154.17 (+0.10%)
NIO   4.02 (+2.81%)
BABA   68.88 (+0.09%)
T   16.23 (+0.68%)
F   12.01 (-0.25%)
MU   112.61 (-3.20%)
GE   153.90 (-1.14%)
CGC   8.12 (+25.12%)
DIS   112.83 (-0.10%)
AMC   2.92 (-2.01%)
PFE   25.33 (-0.35%)
PYPL   62.22 (-1.64%)
XOM   118.24 (-0.33%)
QQQ   423.19 (-0.62%)
AAPL   166.91 (-0.65%)
MSFT   405.39 (-1.57%)
META   501.50 (+1.48%)
GOOGL   156.22 (+0.48%)
AMZN   179.00 (-1.26%)
TSLA   150.48 (-3.20%)
NVDA   844.72 (+0.52%)
AMD   154.17 (+0.10%)
NIO   4.02 (+2.81%)
BABA   68.88 (+0.09%)
T   16.23 (+0.68%)
F   12.01 (-0.25%)
MU   112.61 (-3.20%)
GE   153.90 (-1.14%)
CGC   8.12 (+25.12%)
DIS   112.83 (-0.10%)
AMC   2.92 (-2.01%)
PFE   25.33 (-0.35%)
PYPL   62.22 (-1.64%)
XOM   118.24 (-0.33%)
QQQ   423.19 (-0.62%)
AAPL   166.91 (-0.65%)
MSFT   405.39 (-1.57%)
META   501.50 (+1.48%)
GOOGL   156.22 (+0.48%)
AMZN   179.00 (-1.26%)
TSLA   150.48 (-3.20%)
NVDA   844.72 (+0.52%)
AMD   154.17 (+0.10%)
NIO   4.02 (+2.81%)
BABA   68.88 (+0.09%)
T   16.23 (+0.68%)
F   12.01 (-0.25%)
MU   112.61 (-3.20%)
GE   153.90 (-1.14%)
CGC   8.12 (+25.12%)
DIS   112.83 (-0.10%)
AMC   2.92 (-2.01%)
PFE   25.33 (-0.35%)
PYPL   62.22 (-1.64%)
XOM   118.24 (-0.33%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$165.12
+0.5%
$175.79
$130.96
$182.89
$292.37B0.585.61 million shs2.72 million shs
GSK plc stock logo
GSK
GSK
$39.17
-1.1%
$41.99
$33.33
$43.84
$81.18B0.643.49 million shs1.36 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$744.99
-0.8%
$764.03
$367.35
$800.78
$707.86B0.343.06 million shs1.03 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+1.05%-2.81%-8.00%+0.58%+2.91%
GSK plc stock logo
GSK
GSK
-0.86%-2.67%-6.05%+0.15%+7.67%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.58%-1.36%-1.55%+20.46%+102.99%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbbVie Inc. stock logo
ABBV
AbbVie
4.9075 of 5 stars
2.45.04.23.93.02.52.5
GSK plc stock logo
GSK
GSK
2.6179 of 5 stars
0.03.03.30.02.60.02.5
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8111 of 5 stars
2.44.02.54.02.52.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.77
Moderate Buy$177.437.45% Upside
GSK plc stock logo
GSK
GSK
2.40
HoldN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$728.05-2.27% Downside

Current Analyst Ratings

Latest LLY, ABBV, and GSK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/11/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$650.00 ➝ $723.00
4/3/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
4/2/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$675.00 ➝ $895.00
4/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
3/27/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$185.00 ➝ $195.00
3/22/2024
AbbVie Inc. stock logo
ABBV
AbbVie
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$188.00 ➝ $190.00
3/22/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$850.00
3/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$775.00 ➝ $850.00
3/4/2024
GSK plc stock logo
GSK
GSK
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy
3/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$800.00 ➝ $1,000.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$54.32B5.38$16.06 per share10.28$5.78 per share28.57
GSK plc stock logo
GSK
GSK
$37.71B2.15$5.08 per share7.71$7.74 per share5.06
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B20.74$7.61 per share97.92$11.44 per share65.12

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.86B$2.7360.4813.562.098.95%162.28%14.62%4/26/2024 (Confirmed)
GSK plc stock logo
GSK
GSK
$6.13B$3.0113.018.821.8316.24%51.45%10.57%5/1/2024 (Confirmed)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$5.80128.4540.251.6315.36%51.22%9.94%4/30/2024 (Confirmed)

Latest LLY, ABBV, and GSK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
GSK plc stock logo
GSK
GSK
$0.95N/A-$0.95N/AN/AN/A
4/30/2024N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.61N/A-$2.61N/AN/AN/A  
4/26/2024N/A
AbbVie Inc. stock logo
ABBV
AbbVie
$2.20N/A-$2.20N/AN/AN/A  
2/6/202412/31/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.30$2.49+$0.19$2.56$8.95 billion$9.35 billion    
2/2/202412/31/2023
AbbVie Inc. stock logo
ABBV
AbbVie
$2.76$2.79+$0.03$5.12$14.02 billion$14.30 billion    
1/31/2024Q4 2023
GSK plc stock logo
GSK
GSK
$0.76$0.72-$0.04$1.23$9.79 billion$10.00 billion

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.203.75%+7.84%227.11%52 Years
GSK plc stock logo
GSK
GSK
$1.594.06%-18.20%52.82%1 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.70%+15.15%89.66%10 Years

Latest LLY, ABBV, and GSK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/15/2024
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.553.54%4/12/20244/15/20245/15/2024
2/1/2024
GSK plc stock logo
GSK
GSK
quarterly$0.35643.4%2/22/20242/23/20244/11/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
5.02
0.87
0.76
GSK plc stock logo
GSK
GSK
1.19
0.88
0.62
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.69
0.94
0.73

Ownership

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
GSK plc stock logo
GSK
GSK
15.74%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.25%
GSK plc stock logo
GSK
GSK
10.00%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
50,0001.77 billion1.77 billionOptionable
GSK plc stock logo
GSK
GSK
70,2002.07 billion1.87 billionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.16 million948.93 millionOptionable

LLY, ABBV, and GSK Headlines

SourceHeadline
Eli Lilly and Company (NYSE:LLY)  Shares Down 0.1% Eli Lilly and Company (NYSE:LLY) Shares Down 0.1%
marketbeat.com - April 18 at 2:47 PM
Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), TG Therapeutics (TGTX)Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), TG Therapeutics (TGTX)
markets.businessinsider.com - April 18 at 2:14 PM
As Zepbound shortage grows, Eli Lilly says no immediate end is in sightAs Zepbound shortage grows, Eli Lilly says no immediate end is in sight
msn.com - April 18 at 2:14 PM
Indias Biocon developing its own version of Wegovy, clinical trial likely next yearIndia's Biocon developing its own version of Wegovy, clinical trial likely next year
finance.yahoo.com - April 18 at 2:14 PM
Twin Capital Management Inc. Sells 4,749 Shares of Eli Lilly and Company (NYSE:LLY)Twin Capital Management Inc. Sells 4,749 Shares of Eli Lilly and Company (NYSE:LLY)
marketbeat.com - April 18 at 1:33 PM
Big pharma: cautious optimism ahead of earnings season - analystsBig pharma: cautious optimism ahead of earnings season - analysts
proactiveinvestors.com - April 18 at 11:35 AM
Eli Lillys (LLY) Tirzepatide Meets Goals in Sleep Apnea StudiesEli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies
zacks.com - April 18 at 9:55 AM
Q1 2025 EPS Estimates for Eli Lilly and Company Reduced by Zacks Research (NYSE:LLY)Q1 2025 EPS Estimates for Eli Lilly and Company Reduced by Zacks Research (NYSE:LLY)
marketbeat.com - April 18 at 6:31 AM
2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years2 Growth Stocks That Turned $10,000 Into More Than $100,000 in Just 10 Years
fool.com - April 18 at 5:10 AM
Eli Lillys Weight Loss Drug Zepbound Shows Promise In Reducing Sleep ApneaEli Lilly's Weight Loss Drug Zepbound Shows Promise In Reducing Sleep Apnea
markets.businessinsider.com - April 18 at 12:39 AM
Eli Lilly’s weight-loss drug Zepbound might help cure your sleep apneaEli Lilly’s weight-loss drug Zepbound might help cure your sleep apnea
fastcompany.com - April 18 at 12:39 AM
Even more doses of Eli Lillys Zepbound and Mounjaro are officially in a shortage, FDA saysEven more doses of Eli Lilly's Zepbound and Mounjaro are officially in a shortage, FDA says
msn.com - April 18 at 12:39 AM
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth SankWhy Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
fool.com - April 17 at 6:51 PM
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth SankWhy Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
fool.com - April 17 at 6:51 PM
Daiwa Securities Group Inc. Raises Stock Position in Eli Lilly and Company (NYSE:LLY)Daiwa Securities Group Inc. Raises Stock Position in Eli Lilly and Company (NYSE:LLY)
marketbeat.com - April 17 at 6:50 PM
These Stocks Are Moving the Most Today: United Airlines, Travelers, J.B. Hunt, Eli Lilly, ASML, Alcoa, and MoreThese Stocks Are Moving the Most Today: United Airlines, Travelers, J.B. Hunt, Eli Lilly, ASML, Alcoa, and More
msn.com - April 17 at 2:39 PM
Eli Lilly and Company (NYSE:LLY)  Shares Down 0.5% Eli Lilly and Company (NYSE:LLY) Shares Down 0.5%
marketbeat.com - April 17 at 12:42 PM
Eli Lillys Weight-Loss Treatment Found To Help Those With Sleep ApneaEli Lilly's Weight-Loss Treatment Found To Help Those With Sleep Apnea
investopedia.com - April 17 at 12:15 PM
Wall Street Lunch: Lilly In LimelightWall Street Lunch: Lilly In Limelight
seekingalpha.com - April 17 at 11:27 AM
Most doses of Eli Lillys Zepbound, Mounjaro in short supply through June, FDA saysMost doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says
cnbc.com - April 17 at 11:23 AM
Eli Lilly Stock Pops on Drug Efficacy for Sleep ApneaEli Lilly Stock Pops on Drug Efficacy for Sleep Apnea
schaeffersresearch.com - April 17 at 10:40 AM
Most doses of Lillys Mounjaro and Zepbound in limited availability, US FDA saysMost doses of Lilly's Mounjaro and Zepbound in limited availability, US FDA says
reuters.com - April 17 at 9:38 AM
Eli Lilly, plaintiffs agree to scrap $13.5M insulin pricing settlementEli Lilly, plaintiffs agree to scrap $13.5M insulin pricing settlement
fiercepharma.com - April 17 at 9:38 AM
Another perk of weight-loss drugs? Eli Lillys Zepbound may alleviate sleep apnea, tooAnother perk of weight-loss drugs? Eli Lilly's Zepbound may alleviate sleep apnea, too
msn.com - April 17 at 9:38 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

AbbVie logo

AbbVie

NYSE:ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
GSK logo

GSK

NYSE:GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.